cyrilzakka/clinical-trials huggingface dataset:
Treatment and Medical Care of Patients With Moderate-to-severe Atopic Dermatitis - TREATswitzerland

As structured and detailed data on the management of AD, a common chronic inflammatory skin disease which has a high impact on patients' quality of life and socioeconomic burden, are not available in Switzerland, the planned registry will overcome this gap. It will provide data on the medical care of patients with AD for health care research and allow to study the efficacy and safety of approved and available therapies for AD in daily life.

A prospective, non-interventional, national multicenter study in patients with moderate-to-severe AD. According to the availability of approved systemic drugs for the treatment of AD, the study will include children ≥12 years, adolescents and adult patients.

The general goal of the AD registry TREATswitzerland is to provide the scientific community with a disease-oriented prospective cohort of patients suffering from moderate-to-severe AD.

The primary objective of the AD registry is the documentation of medical care given to patients with moderate-to-severe AD in order to assess the appropriateness of care.

Further objectives of the AD registry are:

1. to evaluate the psychosocial impact of AD;
2. to provide up-to-date epidemiologic data that allow investigating risk factors for favorable or unfavorable disease courses and comorbidities; and
3. to establish a research network and foster clinical research projects.

The study procedures include:

* No study related intervention will be performed
* Patients have to fulfill all inclusion criteria to be enrolled in the study.
* Included patients are prospectively followed for at least 24 months. A maximum duration of follow-up is not intended.
* During the observation period, standardized study visits are performed to prospectively document patient characteristics, clinical data, patient-reported outcomes, reasons for treatment decisions, and satisfaction with treatment.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 12 years
* AD according to the UK Working Party's Diagnostic Criteria (28)
* Moderate to severe AD as defined by
* objective SCORAD \> 20 or IGA ≥ 3 (moderate) or
* currently on systemic antiinflammatory therapy for AD or
* previous systemic antiinflammatory therapy for AD within past 24 months

Exclusion Criteria:

* refusal to sign the informed consent form
Online Support Groups for Depression and Anxiety

The purpose of this study is to determine the effectiveness of online support groups for anxiety and depression.

In recent years the number of online support groups for conditions like depression and anxiety has grown rapidly. Millions of people are thought to be using them around the world. This research aims to help find out whether the use of online support groups is beneficial and to learn more about what happens in these groups.

This research will compare online support groups with expressive writing. Expressive writing involves people writing about their thoughts and feelings, often upsetting ones, for a short period of time. In online support groups giving and receiving support from others can be helpful while expressive writing about emotional issues can be cathartic.

1,000 participants will be recruited online from the UK, USA and Canada and randomly assigned to either an existing online support group or to an expressive writing condition.

Eligibility Criteria:
Inclusion Criteria:

* Self-defined depression \& anxiety
* Resident in the UK, US or Canada
* Access to the internet

Exclusion Criteria:

-
Citicoline, Creatine, and Omega-3 Effects in Middle Age Women

The purpose of this study is to determine the functional effects of a citicoline, creatine, and omega-3 fatty acids combination when administered for a duration of four weeks (28 days) to non-psychiatric adult female participants.

Standard clinical measures for mood and neuropsychological measures of attention, cognitive inhibition and memory will be applied before, during, and after a course of a daily supplementation of citicoline, creatine and omega-3 for 28 days to non-psychiatric adult female participants. We hypothesis that the combination of supplements will improve memory and attention in healthy adult women.

Eligibility Criteria:
Inclusion Criteria:

* Female
* Age 40-60 years

Exclusion Criteria:

* Significant medical condition
* History of co-morbid psychiatric disorders
* Current Axis I or II diagnosis
* Past participation in a pharmacotherapeutic trial
* Head injury with LOC\>5 minutes
* Use of psychotropic medication
* History of fish allergies
* Medical condition associated with clinically significant decreases in coagulability
* Use of anticoagulant medication
Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers

In order to meet the preferences and needs of different patients for injection sites and improve the medication compliance of patients, it is planned to compare the bioavailability, pharmacokinetics, pharmacodynamic and safety data to assess feasibility of multiple injection sites for administration.


Eligibility Criteria:
Inclusion Criteria:

1. Understanding the research procedures and methods, being able to complete the research in accordance with the procedure requirements, and sign the informed consent;
2. The age on the date of signing the informed consent must be ≥18 years old and ≤55 years old;
3. Body mass index (BMI) at screening period must be ≥18.5 kg/m2 and \<30.0 kg/m2, weight of male must≥ 50.0 kg and \<90.0 kg, and female≥ 45.0 kg and \<90.0 kg;
4. The subjects and their female partners are willing to have no reproductive plan from 2 weeks before screening to 6 months after the administration of the study drug, and voluntarily take effective contraceptive measures and do not plan to donate sperm or ovum.

Exclusion Criteria:

1. History of the following diseases or treatments:

   Diseases that affect drug absorption, distribution, metabolism, and excretion determined by the investigator; Serious infection within 3 months before screening; History of drug allergy or atopic allergic disease (asthma, urticaria).
2. Any one of the following tests at Screening period or Baseline period:

   Human immunodeficiency virus antibody (HIV-Ab), syphilis serological examination, hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab) positive; Positive blood pregnancy test.
3. General situation:

   Have a history of drug use or drug abuse; Women who are pregnant or breastfeeding.
4. Subjects who are considered by the investigator to have any other factors which are not suitable for participating in this study.
Augmented Infant Resuscitator to Enhance Newborn Ventilation

Augmented Infant Resuscitator (AIR) is an inexpensive add-on, compatible with nearly every existing bag-valve mask and many types of ventilation equipment. AIR monitors ventilation quality and provides real-time objective feedback and actionable cues to clinicians to both shorten training times and improve resuscitation quality, adoption, retention, and confidence.

Longitudinal, randomized control trial that examined the effectiveness of AIR among 270 participants, with 1,080 recorded ventilation scenarios, and across 20 sites in Uganda and the U.S. Birth attendants - including a mix of midwives, nurses, respiratory therapists, pediatricians, and neonatologists - with recent HBB and/or NRP training were recruited to participate in this randomized control trial. Participants ventilated training mannequins for a fixed duration of time. Participants were randomized to receive visual feedback from AIR (intervention) or have the AIR feedback covered (control). They were then requested to administer effective ventilation and verbally assess the mannequin condition. All mannequins appeared to be identical, but each session's mannequin was randomly selected with an upper airway that was normal, partially leaking, or partially obstructed.

Eligibility Criteria:
Inclusion Criteria:

* Midwives, nurses, respiratory therapists, pediatricians, and neonatologists working as birth attendants in select hospitals in Uganda and the U.S. who are either previous trained in Helping Babies Breathe (HBB) and/or have a current Newborn Resuscitation Program (NRP) certification.

Exclusion Criteria:

* None
Strategies of Revascularization in Patients With ST-segment Elevation Myocardial Infarction (STEMI) and Multivessel Disease

Multivessel disease has been reported to occur between 40 and 60% of patients with ST-segment elevation myocardial infarction (STEMI) and has been associated to a worse prognosis. Multivessel revascularization offers a myriad of potential advantages as enhance of the collateral blood flow, greater myocardial salvage, the stabilization of other lesions that can be potentially vulnerable, and the achievement of a complete revascularization, factor that is associated with a better prognosis. On the other hand, the prolongation of procedural duration, the hazard of contrast induced nephropathy and the peri-procedural complications can limit the widespread of this practice.

To date, very few observational studies have focused in the multivessel revascularization with disparity of results. Whereas ones have observed an increase of adverse cardiovascular events and thus not recommend it, others have shown neutral results.

Stress echocardiography has been shown to be an adequate technique for the diagnosis of coronary artery disease and could be an appropriate tool for selecting the lesions that need to be revascularized because they induce large areas of ischemia. However, this technique has also limitations like the high operator-dependence.

Therefore, the investigators sought to study if the complete multivessel revascularization of patients with STEMI treated by means of primary percutaneous coronary intervention (PCI) has an impact on prognosis compared to a strategy of treating only those non-culprit lesions that produce large areas of ischemia in a stress test.


Eligibility Criteria:
Inclusion Criteria:

* Typical chest pain lasting \>30 minutes with ST-segment elevation \>=1mm in \>=2 contiguous ECG leads or left bundle branch block and presentation \< 48 hours since symptom onset.
* Patients undergoing rescue PCI
* Patients with effective lysis and coronary angiography in less than 24 hours
* Presence of other lesion \>=70% in a non-culprit artery.
* Informed consent

Exclusion Criteria:

* Significant left main disease
* Lesions in vessels \< 2 mm
* Lesions in branches of a main epicardial coronary artery and short irrigation territory
* Previous coronary artery bypass graft (CABG)
* Any coronary intervention in the previous month
* Cardiogenic shock
* Anatomic features no suitable for coronary intervention
* Pregnancy
IMOvifa Perimeter Reference Database

This study will collect data to establish a reference database for the IMOvifa perimeter.

This study will collect data from a reference population to be used as inputs to the calculation of age corrected significance limits for expected visual function sensitivity to establish reference limits for key output parameters for select test patterns of the IMOvifa perimeter device.

Eligibility Criteria:
Inclusion Criteria:

* 22 years of age or older on the date of informed consent
* Able to understand the written informed consent and willing to participate
* IOP ≤ 21 mmHg (each eye)
* BCVA 20/40 or better (each eye)
* Both eyes free of ocular conditions that may affect visual function (at doctor's discretion)

Exclusion Criteria:

* Unable to tolerate ophthalmic imaging and/or VF testing
* History of conditions known to adversely affect visual function (at doctor discretion)
* Spherical Equivalent refractive error outside the range from +6 Diopters
* Cylindrical refractive error outside the range +2.5 Diopters
Botulinum Toxin A for Idiopathic Toe-walking

The purpose of this study is to determine whether botulinum toxin A (BTX) adds a favourable effect to treatment of idiopathic toe-walking with below knee walking casts. The specific hypothesis to be tested is that a combination of BTX and casting is more effective than casting treatment alone in reducing toe-walking in 5-15 year old children. Evaluation methods include 3-D gait analysis, parents' perception of toe-walking frequency, passive joint range of motion measurements, and strength of ankle dorsal extension.


Eligibility Criteria:
Inclusion Criteria:

* Children with idiopathic toe-walking
* 5-15 years of age

Exclusion Criteria:

* Previous treatment for idiopathic toe-walking, such as, Achilles tendon surgery, casting, orthotics, and BTX treatment.
* Flexion contracture beyond -10 degrees in the ankle
Ultrasound Guided Transversus Abdominis Plane (TAP) vs. Trigger Point Injection (TPI) for Abdominal Wall Pain

Patients with chronic abdominal pain- with a component of abdominal wall pain- are often treated with trigger point injections. This study will help to determine if a block within the transversus abdominis plane (TAP) will provide superior analgesic benefit to a trigger point injection as therapy for these patients.

Only patients referred to the Pain Clinic for abdominal trigger point injections for abdominal wall pain will be considered for study recruitment.

Following informed consent, patients will complete a baseline questionnaire in the Pain Clinic which gathers basic demographic data, pain scores and functional scores. Patients will be randomized to receive either a TAP injection or a TPI. Because the TAP injection involves a larger area to be anesthetized, a larger volume of medication will be used.

Thirty minutes after the injection, a sensory exam will be performed on the patient to determine the level of block. At one week, one month, three months and six months after the injection, a staff member will telephone the patient to assess how they are doing. The call will take approximately 10 minutes and will consist of relaying a pain score as well as daily functioning and sleep questions.

Subjects are responsible for all clinical costs associated with the injection.

There is no remuneration offered for study participation.

Eligibility Criteria:
Inclusion Criteria:

Only patients referred to Pain Clinic for a trigger point injection.

* Non-cancer pain greater than 3 months duration.
* Unilateral abdominal pain.
* Positive Carnett's sign (A test in which acute abdominal pain remains unchanged or increases when the muscles of the abdominal wall are tensed.)
* An identifiable abdominal trigger point.

Exclusion Criteria:

* History of chronic psychotic disorder.
* History of dementing illness.
* Active abdominal visceral disease as a known contributor of the pain.
* Abdominal surgery in the past 6 months.
* More than one trigger point.
* Abdominal wall hernias.
* BMI\>40.
The Relationship Between Covid-19 Infection in Pediatric Patients and Secondary Lymphoid Organs

We aimed to find out whether the tonsils and nasal tissues of pediatric patients are the main factors that protects the children's immune system against COVID-19 infection.

Since it is known that the tonsil and adenoid tissues that are known as a secondary lymphoid organ, which form the first line of defense, are more active in childhood than adults, especially in the childhood age group, and since it has been scientifically shown that patients diagnosed with COVID-19 infection in the pediatric age group overcome this disease lightly than adults, we aimed to reveal whether the defined tonsil and adenoid tissues are the main factors that protect the children's immune system against COVID-19 infection.

Eligibility Criteria:
Inclusion Criteria:

* Patients with COVID-19 infection.
* Patients aged between 1-16 years
* Patients whose PCR test becomes negative

Exclusion Criteria:

* Patients with lymphoid tissue malignant disease
* Patients with known lung disease
* Patients with known systemic disease
Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors

The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events associated with PRRT in patients with gastroenteropancreatic primary NETs.

Neuroendocrine tumors (NETs) make up a large range of malignancies that arise from neuroendocrine cells in multiple organs of the body. Hallet et al conducted a large population-based study that demonstrated that 21% of NET patients presented with metastatic disease and another 38% developed metastases after resection of the primary tumor (Hallet et al., 2015). This burden demonstrates the need for effective systemic therapy for advanced NETs. Options for systemic therapy include peptide receptor radionuclide therapy (PRRT).

A need for more prospective series are needed on treatment responses and survival outcomes related to gastroenteropancreatic primary NETs treated with PRRT was identified. Thus the purpose of this study is to collect clinical data related to treatment of gastroenteropancreatic primary NETs s with PRRT. Clinical data related to patient characteristics, treatment responses and survival outcomes related to the treatment of gastroenteropancreatic primary NETs with PRRT and on adverse events and complications related to PRRT treatment will be collected.

Eligibility Criteria:
Inclusion Criteria:

1. \> 18 years of age
2. Diagnosed with gastroenteropancreatic primary NET and has consented to undergo PRRT per the treating physician. Specifically:

   * Will consider other primaries on a case by case basis if dotatate scan (+) and meet all other criteria.
   * Metastatic or Locally Advanced AND Inoperable
   * Clear disease progression on Octreotide over less than 3 years (RECIST 1.1)
   * Presence of disease within 24 weeks as identified by PET/CT scans with Ga-68 DOTATATE reporting the Krenning score for low-grade NET and/or PET/CT scans with FDG for transformation to high-grade NET
   * Well differentiated on path - Ki67 \< 20%
   * Octreotide positive on pathology (if not documented, acceptable if PET/CT imaging shows lesions with Ga-68 DOTATATE uptakeLabs:

     * Cr. \<1.7
     * Hgb \>8
     * WBC \>2K
     * Plt \>75K
     * Bili \< 3x normal limit
   * No Octreotide within 30 days of administration.
3. Willing and able to comply with the protocol requirements
4. Able to comprehend and sign the Informed Consent Form in English.

Exclusion Criteria:

* Do not meet the Study Inclusion Criteria laid out in section 6.3
Fenofibrate Role in Breast Cancer Patients

The aim of the study is to assess the efficacy of fenofibrate in either reversing and/or preventing the development of PIPN in breast cancer patients treated with paclitaxel-based regimen. The primary outcome :clinical improvement of neuropathic pain and grade by 1-CT-CTCAE -VERSION-4 \& FACT/GOG-NT-12 questionnaire and its effect on quality of life (QOL).

The secondary outcome : the efficacy of fenofibrate in either reversing and/or preventing the development of PIPN via alteration of either Nerve growth factor (NGF) or/ and/( NFL).

Ethical committee approval will be obtained from ethics committee of Faculty of Pharmacy, Damanhur University.

2. All participants should agree to take part in this clinical study and will provide informed consent.

3. fifty female patients with diagnosed breast cancer, who are candidates for will be recruited from Damanhur oncology center.

4. All enrolled patients will be randomly assigned into two arms: Group 1 ( Arm A) (n=25: will receive four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week.

Group 2 ( Arm B) (n=25): will receive the same regimen as group1 in addition to 160mg (17 ,18 ) fenofibrate once daily for 3 month.

5. All patients will be submitted to:

* Full patient history and clinical examination.
* Routine follow up before and after each chemotherapy cycle (complete blood picture, liver function tests, renal function tests).
* Serum samples will be collected from patients at the time of admission for measuring the neuropathy biomarkers Nerve growth factor (NGF) and (NFL) to lipid profile .
* Clinical assessment of neuropathic pain using FACT/GOG NtX 12 questionnaire and NCT-CTCAE -VERSION-4 .

  6. All patients will be followed up during paclitaxel treatment period (12 weeks). At the end of paclitaxel treatment, Serum samples will be collected from patients for measuring the biomarkers .

  7. Statistical tests appropriate to the study design will be conducted to evaluate the significance of the results.

  8. Results, conclusion, discussion, and recommendations will be given.

Eligibility Criteria:
Inclusion criteria:

1. included a diagnosis breast cancer with age \> 18 years.
2. Naïve to chemotherapy

Exclusion Criteria:

1. Concurrent administration (statins , cyclosporine) .
2. Advanced liver disease (defined as liver enzyme elevation \>3-fold upper limit of normality, or cirrhosis); chronic kidney disease (CKD, defined as an eGFR \<60 ml min-1 1.73 m-2); acute or chronic pancreatitis and diabetes.
3. Patients with a history of allergy to fenofibrate.
4. Concomitant use of opioids, anticonvulsants, tricyclic antidepressants, other neuropathic pain medication.
5. Pregnancy or breast feeding.
HIV Self-Testing AND Uptake and Retention of PrEP Among Older Adolescent MSM and TGW

This will be a prospective study that will enroll up to 600 older adolescent MSM and TGW from community-based clinics in Bangkok, Chonburi, Chiang Mai, and Songkhla.

All eligible participants will be followed up at month 3, 6, 9, and 12; month 6 and 12 will be mandatory clinic visits, while month 3 and 9 will be either clinic or a virtual visits. For participants accepting PrEP, additional follow-up visit at month 1, 2, 4, and 5 will be appointed; all visits will be either clinic or virtual visits.

Study Sites

The study will take place at the following community-based clinics:

1. SWING DIC, Bangkok, Thailand
2. RSAT DIC, Bangkok, Thailand
3. SWING DIC, Chonburi, Thailand
4. Sister DIC, Chonburi, Thailand
5. Caremat DIC, Chiang Mai, Thailand
6. MPlus DIC, Chiang Mai, Thailand
7. RSAT DIC, Songkhla, Thailand

Eligibility Criteria:
Inclusion Criteria:

1. Thai nationality
2. Age 15-19 years old
3. Men or transgender women who have sex with men
4. HIV-negative at the time of screening
5. Have at least one of the following risks for HIV acquisition in the past 6 months:

   1. Any unprotected receptive anal sex with a male partner
   2. More than 5 male partners, regardless of condom use and serostatus
   3. Has had a bacterial sexually transmitted infection (STI)
   4. Any injected drug use
6. Calculated creatinine clearance (CrCl) ≥ 75 mL/min, as estimated by the Cockcroft- Gault equation
7. Alanine aminotransferase (ALT) ≤ 2.5 x ULN
8. Have signed the informed consent form

Exclusion Criteria:

1. HIV-positive
2. Hepatitis B infection as indicated by positive hepatitis B surface antigen (HBsAg) test at time of screening
3. Known allergy/sensitivity to tenofovir or emtricitabine
Total Laparoscopic Hystrectomy Versus Total Abdominal Hystrectomy

100 patient will be recruited for hystrectomy for benign cause and TLH will be copared to TAH and effect of learning curve will be assessed by comparing operative time between early and lat patients in TLH group


Eligibility Criteria:
Inclusion Criteria:

- Age. More than 40 Uterine size less than 14 weeks No contraindications for laparscopic surgery Benign cause for hystrectomy

Exclusion Criteria:

* virgins Malignancy